Current Chemical Genomics and Translational Medicine

2008, 2 : 16-28
Published online 2008 October 17. DOI: 10.2174/1875397300802010016
Publisher ID: CCGTM-2-16

RESEARCH ARTICLE
A Novel Bioluminescent Protease Assay Using Engineered Firefly Luciferase

Susan S Wigdal , Jessica L Anderson , Gediminas J Vidugiris , John Shultz , Keith V Wood and Frank Fan, *
Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA

* Address correspondence to this author at the Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA; Tel: 608-277-2531; Fax: 608-298-4818; E-mail: frank.fan@promega.com

ABSTRACT

Proteases play important roles in a variety of disease processes. Understanding their biological functions underpins the efforts of drug discovery. We have developed a bioluminescent protease assay using a circularly permuted form of firefly luciferase, wherein the native enzyme termini were joined by a peptide containing a protease site of interest. Protease cleavage of these mutant luciferases greatly activates the enzyme, typically over 100 fold. The mutant luciferase substrates are easily generated by molecular cloning and cell-free translation reactions and thus the protease substrates do not need to be chemically synthesized or purchased. The assay has broad applicability using a variety of proteases and their cognate sites and can sensitively detect protease activity. In this report we further demonstrate its utility for the evaluation of protease recognition sequence specificity and subsequent establishment of an optimized assay for the identification and characterization of protease inhibitors using high throughput screening.